Press-release for stocks published on previous years

Prices are updated after-hours

published : Previous years crawled time : 12:15

save search

APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON AUGUST 11, 2022
Published: 2022-06-30 (Crawled : 12:15) - apyxmedical.com
FNCTF | News | $11.0354 -20.84% 320

Communications

| -6.98% | O: 1.06% H: 0.0% C: 0.0%
APYX | $1.325 -3.99% -4.15% 57K

Health Technology

| -77.88% | O: -4.17% H: 0.0% C: 0.0%
year corporation results

APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO IMPROVE APPEARANCE OF LAX (LOOSE) SKIN
Published: 2022-07-18 (Crawled : 12:15) - apyxmedical.com
APYX | $1.325 -3.99% -4.15% 57K

Health Technology

| -80.12% | O: 18.16% H: 0.0% C: 0.0%
fda clearance renuvion skin corporation

Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
Published: 2021-11-12 (Crawled : 12:15) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K

Health Technology

| 22.63% | O: -0.15% H: 0.0% C: 0.0%
heart therapy

BioLineRx to Report Third Quarter 2021 Results on November 18, 2021
Published: 2021-11-12 (Crawled : 12:15) - prnewswire.com
BLRX | $0.6564 2.55% 2.48% 190K

Health Technology

| -77.02% | O: 0.18% H: 0.0% C: 0.0%
results

Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
Published: 2021-11-12 (Crawled : 12:15) - prnewswire.com
MIST | $1.64 0.61% 0.61% 30K

Health Technology

| -70.84% | O: 0.72% H: 0.0% C: 0.0%
financial results results milestone

BioCryst to Present at Upcoming Investor Conferences
Published: 2021-11-12 (Crawled : 12:15) - globenewswire.com
BCRX | $4.44 -1.33% -1.35% 4.7M

Health Technology

| -64.84% | O: -4.22% H: 0.0% C: 0.0%
conference presentation

Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-11-12 (Crawled : 12:15) - celyad.com
CYAD | $0.47 -12.49% 49K

Health Technology

| -88.45% | O: -0.74% H: 0.0% C: 0.0%
immunotherapy therapy cancer trial car-t preclinical pre-clinical designation

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
Published: 2021-11-12 (Crawled : 12:15) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K

Health Technology

| -51.68% | O: 0.19% H: 0.0% C: 0.0%
phase 1 antibody

Avalon Holdings Corporation Announces Third Quarter Results
Published: 2021-11-12 (Crawled : 12:15) - prnewswire.com
AWX | $2.255 1.79% 0.0% 690

Industrial Services

| -44.91% | O: 3.72% H: 0.0% C: 0.0%
results

Hycroft Files 2021 Third Quarter 10-Q And Reports Financial Results
Published: 2021-11-12 (Crawled : 12:15) - prnewswire.com
HYMC | $3.65 1.96% 1.92% 720K

Non-Energy Minerals

| 249.06% | O: 1.89% H: 0.0% C: 0.0%
financial results results

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing
Published: 2021-11-12 (Crawled : 12:15) - affimed.com
AFMD | $5.15 1.58% 1.55% 64K

Health Technology

| -12.13% | O: -0.17% H: 0.0% C: 0.0%
potential antibody preclinical pre-clinical

Clearday Inc. Enters Into Agreement With Invento Research Inc. and Schedules Demonstration
Published: 2021-11-12 (Crawled : 12:15) - biospace.com/
CLRD | $0.52 21.23% 810

Manufacturing

| Email alert Add to watchlist
research

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
PTGX | $25.61 1.55% 1.52% 450K

Health Technology

| -26.93% | O: 3.64% H: 2.6% C: 1.34%
conference therapeutics

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
LYRA | $5.16 -4.27% -4.46% 230K

Health Technology

| -22.71% | O: 0.57% H: 1.28% C: 0.0%
conference therapeutics

Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
ALKS | $23.86 0.42% 0.42% 2.4M

Health Technology

| -5.64% | O: -1.59% H: 1.86% C: -1.05%
treatment neurodegenerative neurological phase 1 phase 2

Energy and bp broaden joint venture focused on renewable natural gas project development aimed at delivering lower carbon intensity fuels
Published: 2021-11-11 (Crawled : 12:15) - cleanenergyfuels.com
PPRUF | $358.55 37.56% 1.5K

Consumer Non-Durables

| -53.0% | O: -3.34% H: 2.39% C: 2.25%
PPRUY | $36.0023 -0.11% 220K

Manufacturing

| -52.59% | O: -0.39% H: 0.0% C: -0.32%
CLNE 4 | $2.205 -1.56% -1.59% 1.3M

Utilities

| -74.57% | O: -3.77% H: 2.46% C: -2.13%
renewable energy liver natural gas

RADCOM Reports Third Quarter 2021 Results
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
RDCM | $8.71 -3.86% -4.02% 38K

Technology Services

| -22.28% | O: -0.42% H: 0.0% C: -3.31%
results

Shutterstock Promotes SVP of Product Meghan Schoen to Chief Product Officer
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
SSTK | $40.99 0.32% 0.0% 400K

Technology Services

| -67.06% | O: -1.59% H: 0.46% C: -0.71%